WO2008152822A1 - Agent médicinal - Google Patents

Agent médicinal Download PDF

Info

Publication number
WO2008152822A1
WO2008152822A1 PCT/JP2008/001535 JP2008001535W WO2008152822A1 WO 2008152822 A1 WO2008152822 A1 WO 2008152822A1 JP 2008001535 W JP2008001535 W JP 2008001535W WO 2008152822 A1 WO2008152822 A1 WO 2008152822A1
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
agent
medicinal
therapeutic agent
antibody therapeutic
Prior art date
Application number
PCT/JP2008/001535
Other languages
English (en)
Japanese (ja)
Inventor
Andrew Nicol
Hirotake Tokuyama
Tomomi Hagi
Mie Nieda
Masato Muto
Original Assignee
Medinet Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinet Co., Ltd. filed Critical Medinet Co., Ltd.
Priority to JP2009519171A priority Critical patent/JPWO2008152822A1/ja
Publication of WO2008152822A1 publication Critical patent/WO2008152822A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un agent médicinal qui permet d'améliorer la cytotoxicité cellulaire dépendante des anticorps qui se produit in vivo lors de l'administration d'un agent thérapeutique d'anticorps monoclonal; sur un procédé thérapeutique/prophylactique; et sur un adjuvant pour améliorer l'effet d'un agent thérapeutique d'anticorps monoclonal. Une combinaison d'un lymphocyte γδT activé et/ou proliféré par un bisphosphonate et IL-2 et un agent thérapeutique d'anticorps monoclonal peuvent être utilisés en tant qu'agent médicinal. L'agent médicinal présente son effet médicinal de façon synergique à un niveau supérieur par comparaison à un cas où chacun du lymphocyte γδT et de l'agent thérapeutique d'anticorps monoclonal est utilisé seul.
PCT/JP2008/001535 2007-06-15 2008-06-13 Agent médicinal WO2008152822A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009519171A JPWO2008152822A1 (ja) 2007-06-15 2008-06-13 医薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007159398 2007-06-15
JP2007-159398 2007-06-15

Publications (1)

Publication Number Publication Date
WO2008152822A1 true WO2008152822A1 (fr) 2008-12-18

Family

ID=40129436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001535 WO2008152822A1 (fr) 2007-06-15 2008-06-13 Agent médicinal

Country Status (2)

Country Link
JP (1) JPWO2008152822A1 (fr)
WO (1) WO2008152822A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010063847A1 (fr) * 2008-12-04 2010-06-10 Universite Victor Segalen Bordeaux 2 Compositions pour potentialiser les signaux d’apoptose dans des cellules tumorales
WO2013174509A1 (fr) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
JP2015522543A (ja) * 2012-05-23 2015-08-06 ガニメド ファーマシューティカルズ アーゲー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
WO2016005752A1 (fr) * 2014-07-09 2016-01-14 Tc Biopharm Ltd Lymphocytes t gamma delta et leurs utilisations
JP2016510721A (ja) * 2013-02-20 2016-04-11 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US10881688B2 (en) 2015-04-15 2021-01-05 Tc Biopharm Ltd Modified gamma delta T cells and uses thereof
EP4119582A1 (fr) * 2012-05-23 2023-01-18 Astellas Pharma Inc. Thérapie d'association comprenant des anticorps contre la claudine 18.2 pour le traitement du cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030223998A1 (en) * 2002-02-27 2003-12-04 Lamb Lawrence S. Targeted immunotherapy of acute lymphoblastic leukemia (ALL)
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
WO2006006720A1 (fr) * 2004-07-13 2006-01-19 Medinet., Co.Ltd MÉTHODE POUR FAIRE LA CULTURE DES CELLULES ϜδT, LES CELLULES ϜδT ET UN REMÈDE/TRAITEMENT PRÉVENTIF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
US20030223998A1 (en) * 2002-02-27 2003-12-04 Lamb Lawrence S. Targeted immunotherapy of acute lymphoblastic leukemia (ALL)
WO2006006720A1 (fr) * 2004-07-13 2006-01-19 Medinet., Co.Ltd MÉTHODE POUR FAIRE LA CULTURE DES CELLULES ϜδT, LES CELLULES ϜδT ET UN REMÈDE/TRAITEMENT PRÉVENTIF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERRINI S. ET AL.: "Retargeting of T-cell-receptor gamma/delta-pos. lymphocytes against tumor cells by bispecific monoclonal antibodies. Induction of cytolytic activity and lymphokine production", INTERNATIONAL JOURNAL OF CANCER, no. SUPPL. 4, 1989, pages 53 - 55 *
ROSSI J.-F. ET AL.: "Enhancing lysis of B cell lymphoma by innovative gamma delta T cell immunotherapies using agonist IPH1101 (phosphotim, BrHPP)", BLOOD, vol. 108, no. 11, 2006, pages 391B, XP008083238 *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US11739139B2 (en) 2005-11-24 2023-08-29 Astellas Pharma Inc. Monoclonal antibodies against Claudin-18 for treatment of cancer
US10738108B2 (en) 2005-11-24 2020-08-11 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
US10174104B2 (en) 2005-11-24 2019-01-08 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10017564B2 (en) 2005-11-24 2018-07-10 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
WO2010063847A1 (fr) * 2008-12-04 2010-06-10 Universite Victor Segalen Bordeaux 2 Compositions pour potentialiser les signaux d’apoptose dans des cellules tumorales
KR20200140387A (ko) * 2012-05-23 2020-12-15 가니메드 파마슈티칼스 게엠베하 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 조합 요법
AU2018201856B2 (en) * 2012-05-23 2020-06-18 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US12059464B2 (en) 2012-05-23 2024-08-13 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
WO2013174509A1 (fr) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
KR102514338B1 (ko) 2012-05-23 2023-03-28 가니메드 파마슈티칼스 게엠베하 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 조합 요법
CN107412773A (zh) * 2012-05-23 2017-12-01 加尼梅德药物公司 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗
AU2013265637B2 (en) * 2012-05-23 2017-12-21 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
JP2018002724A (ja) * 2012-05-23 2018-01-11 ガニメド ファーマシューティカルズ ゲーエムベーハー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
JP2018035155A (ja) * 2012-05-23 2018-03-08 ガニメド ファーマシューティカルズ ゲーエムベーハー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
AU2013265637B8 (en) * 2012-05-23 2018-04-26 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
JP2015522543A (ja) * 2012-05-23 2015-08-06 ガニメド ファーマシューティカルズ アーゲー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
US10022444B2 (en) 2012-05-23 2018-07-17 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
EP4119582A1 (fr) * 2012-05-23 2023-01-18 Astellas Pharma Inc. Thérapie d'association comprenant des anticorps contre la claudine 18.2 pour le traitement du cancer
CN107412773B (zh) * 2012-05-23 2021-04-06 加尼梅德药物公司 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗
WO2013174404A1 (fr) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
JP2015518838A (ja) * 2012-05-23 2015-07-06 ガニメド ファーマシューティカルズ アーゲー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
KR102188001B1 (ko) 2012-05-23 2020-12-07 가니메드 파마슈티칼스 게엠베하 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 조합 요법
JP2019104747A (ja) * 2012-05-23 2019-06-27 ガニメド ファーマシューティカルズ ゲーエムベーハー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
CN104427999A (zh) * 2012-05-23 2015-03-18 加尼梅德药物公司 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗
US9433675B2 (en) 2012-05-23 2016-09-06 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
KR20150027112A (ko) * 2012-05-23 2015-03-11 가니메드 파마슈티칼스 아게 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 조합 요법
US10813996B2 (en) 2012-05-23 2020-10-27 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
JP7051931B2 (ja) 2013-02-20 2022-04-11 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP7299369B2 (ja) 2013-02-20 2023-06-27 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP2016510721A (ja) * 2013-02-20 2016-04-11 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
US10946069B2 (en) 2013-02-20 2021-03-16 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
JP2018197260A (ja) * 2013-02-20 2018-12-13 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP2020125329A (ja) * 2013-02-20 2020-08-20 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP2022088550A (ja) * 2013-02-20 2022-06-14 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
US11826402B2 (en) 2013-02-20 2023-11-28 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
US10314890B2 (en) 2013-02-20 2019-06-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
US9770487B2 (en) 2013-02-20 2017-09-26 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US11395852B2 (en) 2013-03-18 2022-07-26 Astellas Pharma Inc. Therapy involving antibodies against Claudin 18.2 for treatment of cancer
WO2016005752A1 (fr) * 2014-07-09 2016-01-14 Tc Biopharm Ltd Lymphocytes t gamma delta et leurs utilisations
US10881688B2 (en) 2015-04-15 2021-01-05 Tc Biopharm Ltd Modified gamma delta T cells and uses thereof

Also Published As

Publication number Publication date
JPWO2008152822A1 (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2008152822A1 (fr) Agent médicinal
WO2009099719A3 (fr) Compositions et procédés de traitement d'une tumeur d'origine hématopoïétique
WO2008113834A3 (fr) Antigènes c5 et leurs utilisations
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
WO2009089494A3 (fr) Compositions pharmaceutiques
NZ620326A (en) Cd37 immunotherapeutic combination therapies and uses thereof
WO2010062581A3 (fr) Composition botanique pour une réparation cutanée optimisée et utilisations associées
MX2010005676A (es) Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
WO2008003007A3 (fr) Compositions et procédés destinés au traitement d'infections parasitaires
WO2007127273A3 (fr) Procédés et compositions permettant de modifier la fonction cellulaire
WO2010132882A3 (fr) Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation
UA96076C2 (en) Use of trans-clomiphene
WO2010151755A3 (fr) Traitement de maladies inflammatoires à l'aide du microarn mir-124
WO2012015741A3 (fr) Polythérapie pour le traitement du cancer comprenant un inhibiteur d'igf-1r et un inhibiteur d'akt
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
WO2007100561A3 (fr) Utilisation de dha et d'ara pour la preparation d'une composition destinee a la prevention ou au traitement de l'obesite
WO2019067405A3 (fr) Formulation de fenfluramine compatible avec un régime cétogène
MX2009012920A (es) Compuestos heptaciclicos y usos farmaceuticos de los mismos para la prevencion y tratamiento de diabetes y sindrome metabolico.
NZ578065A (en) Methods for treating psoriasis with an antibody which binds to an epitope
NZ598722A (en) Methods for treating psoriasis
WO2011075822A8 (fr) Compositions immunogènes et méthodes correspondantes
AU2013257482A1 (en) Methods and compositions for administration of oxybutynin
WO2011044523A3 (fr) Compositions et procédés destinés à traiter l'obésité
WO2008016730A3 (fr) Compositions et procédés pour réduire la graisse cellulaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764130

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009519171

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08764130

Country of ref document: EP

Kind code of ref document: A1